Health Catalyst, Inc.

Health Catalyst, Inc. (HCAT) Market Cap

Health Catalyst, Inc. has a market capitalization of $154.4M.

Price: $2.09

0.01 (0.48%)

Market Cap: 154.44M

NASDAQ · time unavailable

CEO: Benjamin Albert

Sector: Healthcare

Industry: Medical - Healthcare Information Services

IPO Date: 2019-07-25

Website: https://www.healthcatalyst.com

Health Catalyst, Inc. (HCAT) - Company Information

Market Cap: 154.44M|Sector: Healthcare

Company Profile

Health Catalyst, Inc. equips healthcare providers with crucial data and analytical technologies, alongside specialized services. Their extensive product line features a robust, enterprise-level data and analytics platform designed specifically for the healthcare sector. They additionally offer advanced artificial intelligence (AI) and data science solutions that integrate AI seamlessly into existing business intelligence tools, thereby enhancing analytical precision. The company's services also cover population health management, which identifies areas for improvement throughout the patient care journey, offering actionable recommendations and automated processes. For financial effectiveness, they provide critical insights into cost analysis, workforce efficiency, and revenue maximization. Moreover, Health Catalyst contributes to improving quality and safety by leveraging clinical and patient safety data, sophisticated analytics, and expert consulting. They also facilitate a national data ecosystem, promoting collaborative thought leadership and shared knowledge to generate groundbreaking insights that redefine healthcare delivery. Established in 2008 and based in South Jordan, Utah, the company was formerly known as HQC Holdings, Inc. before officially becoming Health Catalyst, Inc. in March 2017.

Analyst Sentiment

60%
Buy

From 7 Active Polls

1Y Forecast: $2.38

▲ +13.9% Potential Upside

Consensus Target Metrics

Low Bound

$2

Median

$2

High Bound

$3

Average

$2

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$2.38
▲ +13.88% Upside
Low Target
$1.75
-16% Risk
Median Target
$2.38
14% Mid
High Target
$3.00
44% Max
Consensus
Buy
12 / 22 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)15492170201262311441492360
Enterprise Value ($M)265203290332385371594528407
Price to Earnings Ratio (P/E)-0.56-0.21-0.47-2.23-1.60-3.24-5.36-8.48-6.60
Price/Earnings-to-Growth Ratio (PEG)-0.97-1.26-14.27-4.18
Price to Sales Ratio (P/S)0.511.302.272.633.253.915.546.444.74
Price to Book Ratio (P/B)1.100.670.690.600.760.821.211.391.01
Price to Free Cash Flow Ratio (P/FCF)16.846.7917.60-38.05-29.94-796.26-52.75274.39-132.54
Enterprise Value to Sales (EV/Sales)2.873.884.364.764.677.466.925.36
Enterprise Value to EBITDA (EV/EBITDA)-1.38-2.16-4.02-84.38-17.15-95.33-238.88-78.43-425.91
Debt to Equity Ratio-0.581.230.700.520.501.071.101.030.70

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 HEALTH CATALYST INC (HCAT) — Investment Overview

🧩 Business Model Overview

Health Catalyst provides healthcare-focused data and analytics software paired with implementation and outcome-oriented services. The company’s platform is deployed inside health systems and other providers to standardize clinical and operational data, generate measurement frameworks, and support continuous improvement initiatives (e.g., quality, safety, throughput, and cost-out workflows).

In practice, value is created through a combination of (1) data integration and governance that makes performance metrics trustworthy, (2) analytics and workflow tooling that operationalizes those metrics, and (3) change-management and advisory services that embed analytics into day-to-day decision-making. This “platform + enablement” model tends to increase customer stickiness compared with tools purchased for one-off reporting needs.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by recurring software arrangements (subscription- or license-like components) supplemented by professional services and support. The recurring component supports more stable monetization as customers renew and expand usage across departments and care lines. Services revenue typically reflects deployment, data onboarding, configuration, training, and ongoing optimization.

Margin structure is influenced by the mix of software versus services and the degree of repeatability in deployments. Software-like revenue generally carries higher gross margins than implementation and consulting work, while services can moderate near-term margins but also accelerates platform adoption by reducing customer effort and execution risk.

🧠 Competitive Advantages & Market Positioning

Health Catalyst’s moat is rooted in high switching costs and data/analytics lock-in (often described as data gravity). Once a health system has invested in integrating data sources, mapping clinical/operational definitions, and operationalizing analytics into governance and improvement cycles, migrating to an alternative platform typically requires rework across data pipelines, metric definitions, workflow logic, and user adoption.

In addition, the company’s positioning emphasizes healthcare-specific deployment practices and measurable operational outcomes, which raises the barrier for general-purpose analytics tools. The platform’s utility improves with broader internal adoption, reinforcing stickiness as teams rely on shared definitions and recurring performance measurement.

  • Primary competitors (examples): Optum (UnitedHealth Group), SAS (healthcare analytics/software), and Epic (Cerner-adjacent ecosystem via EHR-native reporting and analytics).
  • Contrast in focus: Optum and Epic have large distribution channels through payer/provider footprints and EHR-adjacent ecosystems; SAS competes as a broader analytics platform with fewer healthcare workflow “out-of-the-box” dynamics. Health Catalyst’s differentiation is the integrated healthcare analytics approach centered on embedment into quality/operations improvement cycles, not only visualization or standalone modeling.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, growth is supported by secular demand for analytics that ties operational metrics to care delivery and financial performance. Key drivers include:

  • Value-based care and quality reporting: Incentive structures that reward outcomes increase the need for reliable measurement, standardized data definitions, and performance monitoring.
  • Operational efficiency imperatives: Providers face ongoing cost pressure, supporting adoption of analytics that improve throughput, resource utilization, and process reliability.
  • Data modernization and interoperability: As organizations expand data sources (clinical, claims, operational), demand grows for governance and analytics layers that can integrate and operationalize heterogeneous data.
  • Expansion within existing accounts: Platform adoption typically begins in targeted initiatives and expands to additional departments, service lines, and measurement domains—supporting a durable land-and-expand dynamic.
  • Automation and advanced analytics adoption: AI-enabled insights increase interest in scalable analytics infrastructure; the platform’s role as the “measurement and workflow layer” can benefit as more analytics workloads are added.

⚠ Risk Factors to Monitor

  • Implementation and adoption risk: Realizing benefits depends on successful data integration, workflow fit, and clinician/operations engagement; underwhelming deployments can increase churn or slow expansion.
  • Competitive pressure from EHR ecosystems and large analytics vendors: EHR vendors and enterprise analytics suppliers can bundle reporting capabilities, potentially compressing budgets for standalone analytics.
  • Regulatory and data privacy exposure: Healthcare data handling requires strict adherence to HIPAA and related privacy/security requirements; breaches or compliance failures would be highly damaging.
  • Technology commoditization: General-purpose analytics and model-building tooling can reduce differentiation if customers treat analytics as a commodity; differentiation must persist through workflow integration and governance.
  • Sales execution and budget cycles: Healthcare purchasing can be slow, and adoption can be sensitive to system-wide prioritization and reimbursement uncertainty.

📊 Valuation & Market View

Market valuation for healthcare analytics and software businesses typically emphasizes SaaS-like characteristics such as recurring revenue durability, customer retention, expansion efficiency, and gross margin trajectory. Depending on profitability and accounting treatment, investors may look to metrics such as EV/ARR or P/S, with sentiment often influenced by:

  • Recurring revenue growth quality (renewals, net retention/expansion)
  • Gross margin stability driven by software mix and service leverage
  • Operating leverage as implementation becomes more repeatable
  • Sales efficiency and backlog/contracting momentum reflecting pipeline conversion

A favorable valuation backdrop generally corresponds to evidence that customer outcomes translate into multi-site expansion and durable platform adoption rather than one-time deployments.

🔍 Investment Takeaway

Health Catalyst’s long-term investment case rests on structural switching costs created by healthcare data integration, standardized metric governance, and embedded analytics workflows. While large incumbents and general analytics platforms pose competitive threats, Health Catalyst’s healthcare-specific platform-and-enablement model supports account expansion and durability if implementation quality and customer outcomes remain strong. The key variables to underwrite are recurring revenue retention, expansion efficiency, and continued differentiation through measurable operational impact.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for HCAT.

globenewswire.com2026-07-28

Health Catalyst to Announce Second Quarter 2026 Operating Results and Host Conference Call on Thursday, August 6, 2026

SALT LAKE CITY, July 28, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its second quarter 2026 operating results on Thursday, August 6, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

marketbeat.com2026-07-16

Health Catalyst Investors Approve Directors, Pay; Board Declassification Fails

Health Catalyst NASDAQ: HCAT stockholders approved three of four proposals presented at the company's 2026 annual meeting, including the election of two directors, ratification of the company's auditor and an advisory vote on executive compensation. A proposal to phase out the company's classified board structure did not receive the required level of support.

globenewswire.com2026-06-16

Health Catalyst to Participate in Upcoming Investor Conference

SALT LAKE CITY, June 16, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that members of senior management will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference, including a panel discussion titled “AI ROI in Healthcare: Real vs Hype Debate,” with Ben Albert, Chief Executive Officer, on Wednesday, June 24, 2026, at 3:30pm ET.

prnewswire.com2026-06-04

Med-Metrix Enters Into Definitive Agreement to Acquire Vitalware to Enhance Coding Accuracy and Net Revenue Yield

PARSIPPANY, N.J., June 4, 2026 /PRNewswire/ -- Med-Metrix, LLC ("Med-Metrix"), backed by Harvest Partners and A&M Capital Partners, today announced it has entered into a definitive agreement to acquire Vitalware, an industry-leading revenue workflow and analytics software business owned by Health Catalyst (NASDAQ: HCAT).

globenewswire.com2026-06-04

Health Catalyst to Divest Vitalware for $147 Million, Accelerating Strategic Transformation

Health Catalyst today announced it has signed a definitive agreement to divest Vitalware, its mid-revenue cycle business, to Med-Metrix for $147 million.

seekingalpha.com2026-05-12

Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript

Health Catalyst, Inc. (HCAT) Q1 2026 Earnings Call Transcript

marketbeat.com2026-05-11

Health Catalyst Q1 Earnings Call Highlights

Health Catalyst NASDAQ: HCAT reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company's operating model, reducing costs and shifting the business further toward technology-led growth.

zacks.com2026-05-11

Health Catalyst (HCAT) Q1 Earnings and Revenues Surpass Estimates

Health Catalyst (HCAT) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of $0.01 per share. This compares to earnings of $0.01 per share a year ago.

zacks.com2026-05-11

Compared to Estimates, Health Catalyst (HCAT) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Health Catalyst (HCAT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

globenewswire.com2026-05-11

Health Catalyst Reports First Quarter 2026 Results

SALT LAKE CITY, May 11, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst,” Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended March 31, 2026. “We delivered solid first quarter results, with revenue and adjusted EBITDA exceeding expectations,” said Ben Albert, Chief Executive Officer of Health Catalyst.

zacks.com2026-05-07

Seeking Clues to Health Catalyst (HCAT) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Evaluate the expected performance of Health Catalyst (HCAT) for the quarter ended March 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

globenewswire.com2026-05-01

Health Catalyst to Announce First Quarter 2026 Operating Results and Host Conference Call on Monday, May 11, 2026

SALT LAKE CITY, May 01, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, will release its first quarter 2026 operating results on Monday, May 11, 2026, after market close. In conjunction, the company will host a conference call to review the results at 5:00 pm ET on the same day.

globenewswire.com2026-04-30

Health Catalyst Appoints Steve Nelson, President of Aetna, to Its Board of Directors

SALT LAKE CITY, April 30, 2026 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. (“Health Catalyst”, Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today announced that Steve Nelson, Executive Vice President and President of Aetna, a CVS Health company, has been appointed to its Board of Directors, effective May 1, 2026.  Nelson's appointment follows the naming of Ben Albert as CEO and Justin Spencer as Chairman of the Board earlier this year, continuing a deliberate pattern of leadership moves designed to accelerate the company's transformation– executing on a single, coordinated strategy to help health systems address cost, clinical outcomes, and consumer experience as one imperative.

defenseworld.net2026-03-19

Health Catalyst (NASDAQ:HCAT) versus MDxHealth (NASDAQ:MDXH) Head to Head Comparison

MDxHealth (NASDAQ: MDXH - Get Free Report) and Health Catalyst (NASDAQ: HCAT - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings and dividends. Volatility and Risk MDxHealth has a beta of

defenseworld.net2026-03-15

Health Catalyst, Inc. (NASDAQ:HCAT) Given Consensus Recommendation of “Hold” by Brokerages

Health Catalyst, Inc. (NASDAQ: HCAT - Get Free Report) has earned an average recommendation of "Hold" from the thirteen ratings firms that are currently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, seven have given a hold recommendation and five have issued a buy recommendation on the company. The

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"HCAT reported Q1’26 revenue of $70.8M and net loss of $111.0M (EPS -$1.53). Revenue was down -5.3% QoQ (from $74.7M in Q4’25) and down -10.8% YoY (from $79.4M in Q1’25). Net loss worsened to -$111.0M, down -21.9% QoQ versus -$91.0M in Q4’25 and down -?% YoY versus -$23.7M in Q1’25 (losses expanded materially). Profitability deteriorated sharply: gross margin remained strong on a GAAP basis at ~50.1%, but operating loss deepened (operating margin -150.5%) with EBITDA at -$103.5M. Operating expense pressure is evident across the P&L, while the single-quarter pattern shows improvement in Q4’25 (operating profit positive) followed by a relapse in Q1’26. Cash flow was modestly positive: operating cash flow was $18.5M and free cash flow was $18.2M in Q1’26, versus $9.9M operating cash in Q4’25, indicating some near-term cash generation despite GAAP losses. Balance sheet liquidity appears solid with $108.8M cash & short-term investments and total equity of $138.1M. However, total assets declined QoQ ($412.2M vs $502.6M), and leverage remains manageable (net debt of about -$41.0M), driven by large cash/investments swings rather than earnings strength. From a shareholder returns perspective, the stock is materially down: price is $1.32 with -64.8% 1y change, which strongly hurts total return despite having $0 dividends and no buybacks reported in the quarter. Analyst consensus fair value/target (~$2.5) suggests limited upside without a clear path to sustainable profitability."

Revenue Growth

Neutral

Revenue declined -5.3% QoQ (74.7M→70.8M) and -10.8% YoY (79.4M→70.8M), indicating a weakening demand/scale trend.

Profitability

Neutral

GAAP net margin fell to -156.9% in Q1’26; net loss expanded sharply YoY (vs -29.9% net margin in Q1’25) and operating margin dropped to -150.5% (vs +51.8% in Q4’25). EBITDA turned deeply negative (-$103.5M).

Cash Flow Quality

Caution

Despite large GAAP losses, operating cash flow was positive ($18.5M) and free cash flow was $18.2M in Q1’26, improving QoQ (from $9.9M OCF). No dividends; buybacks not shown.

Leverage & Balance Sheet

Fair

Liquidity looks supportive: cash & short-term investments of $108.8M and net debt ~- $41.0M (net cash). Equity is $138.1M QoQ down from $245.8M, and total assets fell to $412.2M from $502.6M.

Shareholder Returns

Neutral

Total shareholder return is weak given the large price drawdown (-64.8% over 1y). No dividend income and no buybacks reported, so capital appreciation is negative.

Analyst Sentiment & Valuation

Caution

Street targets (consensus ~$2.5; current ~$1.32) imply potential upside, but the trajectory of losses and revenue declines limits confidence in valuation support.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Health Catalyst’s Q1 2026 showed early traction from its operating transformation: revenue of $70.8M exceeded the $68M–$70M guide range and adjusted EBITDA of $9.1M beat the $7M–$8M range. Margin improved year over year (+230 bps adjusted gross margin to 51.5%) even as management highlighted ongoing Ignite migration cost headwinds (duplicate hosting and HIE data loading before recognition). The core tension is migration-driven revenue pressure: management expects to retain at least $22M of $52M at-risk ARR, leaving ~$30M impacting 2026 ($20M) and 2027 ($10M). Project NEXUS targets ~$30M annual run-rate savings with ~$4M restructuring charges in Q2. Guidance reflects this mix: full-year 2026 revenue $260M–$265M and adjusted EBITDA $30M–$33M. Bookings momentum and “very positive” Ignite Intelligence feedback support a more durable, technology-led model, but conversion and churn execution remain the primary near-term risks.

AI IconGrowth Catalysts

  • Ignite Intelligence rollout with “very positive” early feedback, especially on cost management; management cites measurable improvement tied to HCAT’s 18 years of proprietary improvement data.
  • AI embedded in domain solutions (cost, clinical quality, consumer experience/ambulatory growth) using “AI agents” on top of the improvement data layer.
  • Strong Q1 bookings ($22M–$26M new bookings expected over 2026) supporting commercial momentum in the second half and pipeline for Q2.
  • Project NEXUS engineering model (AI development agents + “pods”) increasing story points delivered per developer by up to 100% in pilots.

Business Development

  • Board addition: Steve Nelson (President of Aetna; former CEO of UnitedHealthcare, Gen Med & Duly Health in Care) cited as part of board refresh; no customer contract named.
  • Competitive landscape referenced: Databricks and Snowflake cited as data-platform layer enablers that lack HCAT’s intelligence layer.

AI IconFinancial Highlights

  • Revenue: $70.8M in Q1 2026 exceeded high end of guided range ($68M–$70M).
  • Adjusted EBITDA: $9.1M exceeded high end of guided range ($7M–$8M).
  • Adjusted net income per share: $0.02; weighted avg shares 72.6M.
  • Adjusted gross margin: 51.5% vs 49.2% prior-year period (+230 bps).
  • Adjusted technology gross margin: 55.3% (professional services 19.4%).
  • Technology gross margin headwinds: duplicate hosting costs from Ignite migrations and heavy data loading costs for HIE deployments before revenue recognition.
  • Operating expense leverage: adjusted operating expenses were $27.3M (39% of revenue) vs $32.8M (41%) in Q1 2025.
  • Project NEXUS: expected annual run-rate cost savings of ~$30M (direct ~$22M from 9% headcount reduction and non-headcount spend reductions; indirect ~$8M from closing open headcount and canceling planned expenses).
  • Full-year outlook reflects migration-related pressure: management states majority of migration-related revenue pressure absorbed in 2026.
  • ARR/downsells/churn framework: $12.5M ARR notified downselling churn; ~$52M potentially at-risk ARR; post-review expectation to retain at least $22M, leaving ~$30M at risk (impact ~$20M in 2026 and $10M in 2027).

AI IconCapital Funding

  • Cash position: approximately $108.8M cash, cash equivalents, and short-term investments at quarter-end; +$13.1M vs Dec 31, 2025.
  • No buyback or new debt amounts disclosed in the transcript.

AI IconStrategy & Ops

  • Operating model transformation: Project NEXUS to simplify organization and consolidate under “1 company / 1 commercial approach / 1 client-facing team / 1 set of standards.”
  • Restructuring charges: expected total Q2 2026 restructuring charges of ~$4M; majority incurred in Q2 with substantial completion by year-end.
  • Cost trajectory: quarterly adjusted operating expenses expected to decrease by $3M–$4M vs Q1; quarterly adjusted cost of revenue expected to decrease by $1M–$2M starting Q2 and ramping through 2H 2026.
  • Services mix shift: management expects services shrink as a % of revenue while retaining wraparound services (e.g., chart abstraction) and infusing more AI, but still providing services where needed to meet clients.
  • Migration management change: line-by-line review of remaining DAS to Ignite migration accounts; not one-size-fits-all; options allowing extended time on DAS.
  • Engineering efficiency: piloted development pods with proprietary AI development agents; up to 100% increase in story points delivered per developer.

AI IconMarket Outlook

  • Full-year 2026 guidance: total revenue $260M–$265M; adjusted EBITDA $30M–$33M.
  • Q2 2026 guidance: total revenue $68M–$70M; adjusted EBITDA $9M–$10M.
  • Revenue pressure framing: migration impact temporary, expected “generally through the strength of the migration at the end of 2027,” with 2026 absorption of the majority.
  • Services segment expectation: exiting 2026, Services segment between $55M and $65M annually.
  • Bookings expectation for 2026: $22M–$26M new bookings (includes all ARR and non-recurring revenue); management expects prompt conversion to revenue (typically 3–6 months).
  • Adjusted technology gross margin: expected to fluctuate modestly and finish year in the mid-60s.
  • Adjusted professional services gross margin: expected to decline over the year; full-year expectation “mid- to low teens.”

AI IconRisks & Headwinds

  • Migration-driven revenue pressure/churn dynamic from prior rigid migration timelines; management links this to 2026 churn/revenue pressure.
  • Ignite migration cost-mismatch: duplicate hosting costs and heavy data loading costs associated with HIE deployments depress technology gross margin until revenue recognition.
  • At-risk ARR uncertainty: ~$30M at-risk ARR remaining after retaining at least $22M; magnitude split expected $20M impact in 2026 and $10M in 2027.
  • Churn not purely infrastructure: management acknowledges some application-side churn/downsell alongside data infrastructure-focused risk.
  • Higher ROI threshold in market: “bar is definitely higher” for health systems; longer decision processes and skepticism vs prior baseline expectations.

Q&A: Analyst Interest

  • Ignite Intelligence customer response + budget comparisons: analysts asked about customers’ AI budgeting and whether they are evaluating build vs buy. Management cited “really, really positive” feedback on early AI cost-management capabilities, stressing differentiation from HCAT’s 18-year proprietary intelligence layer and expecting meaningful contribution to future growth.
  • Data platform commoditization and competitive differentiation: analysts asked when commoditization occurred, competitors, and how much revenue is attributable to data infrastructure vs the intelligence layer. Management said Databricks/Snowflake enable data-platform layers but lack HCAT’s intelligence; the intelligence sits on top of client platforms and preserves application relationships.
  • ARR downsell/churn breakdown and conversion timing: analysts requested delineation of the $52M at-risk amount and what defines $22M retention vs $30M risk, plus how quickly bookings convert to revenue. Management described line-by-line account plans and typical 3–6 month booking-to-revenue conversion, varying by project/technology.

Sentiment: MIXED

Note: This summary was synthesized by AI from the HCAT Q1 2026 (ended March 31, 2026) earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for HCAT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (HCAT)

© 2026 Stock Market Info — Health Catalyst, Inc. (HCAT) Financial Profile